SCHEMBL21323101

SCHEMBL21323101

O=C(CCc1ccc(C(F)(F)F)nc1)N1CC2CN(C(=O)c3ccc4[nH]nnc4c3)CC2C1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ATXN2 Q99700 6/20 0.41
▸ ENPP2 Q13822 5/20 0.41
▸ DGAT2 Q96PD7 1/20 0.41
▸ CHRNA7 P36544 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ SCN9A Q15858 3/20 0.34
▸ DAO P14920 1/20 0.34
▸ SCN5A Q14524 1/20 0.33
▸ TLR9 Q9NR96 1/20 0.33
▸ TLR8 Q9NR97 1/20 0.33
▸ TLR7 Q9NYK1 1/20 0.33
▸ GPBAR1 Q8TDU6 1/20 0.33
▸ MOGAT2 Q3SYC2 1/20 0.33
▸ SCN10A Q9Y5Y9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16963655 1.00 ATXN2 (0.41) ATXN2ENPP2DGAT2CHRNA7KCNH2
SCHEMBL16962369 0.88 ENPP2 (0.43) ATXN2ENPP2DGAT2TLR9TLR8
SCHEMBL21323349 0.88 ENPP2 (0.43) ATXN2ENPP2DGAT2TLR9TLR8
SCHEMBL16963657 0.85 ENPP2 (0.34) ATXN2ENPP2DGAT2CHRNA7KCNH2
SCHEMBL21323373 0.84 ATXN2 (0.41) ATXN2ENPP2DGAT2CHRNA7KCNH2
SCHEMBL16963800 0.84 ATXN2 (0.41) ATXN2ENPP2DGAT2CHRNA7KCNH2
SCHEMBL21323237 0.84 GHSR (0.39) ATXN2ENPP2DGAT2TLR9TLR8
SCHEMBL16962954 0.84 GHSR (0.39) ATXN2ENPP2DGAT2TLR9TLR8
SCHEMBL16963033 0.83 ENPP2 (0.57) ATXN2ENPP2DGAT2KCNH2GPBAR1
SCHEMBL16963383 0.83 ENPP2 (0.57) ATXN2ENPP2DGAT2KCNH2GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900669-B1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES HOFFMANN LA ROCHE (CH) 2019-09-04 — — EP disclosed
Send feedback